Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (231-240 of 306) with videos related to

Pageof 31
Sort By:
Alimentary Pharmacology & Therapeutics|December 13, 2022
A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitisZobair Younossi, Naim Alkhouri, Ken Cusi, et al.
Hepatology (Baltimore, Md.)|June 16, 2016
Receptor interacting protein 3 protects mice from high-fat diet-induced liver injurySanjoy Roychowdhury, Rebecca L McCullough, Carlos Sanz-Garcia, et al.
Journal of Hepatology|February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASHStephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Journal of Hepatology|December 15, 2010
An apoptosis panel for nonalcoholic steatohepatitis diagnosisTarek I Abu-Rajab Tamimi, Hesham M Elgouhari, Naim Alkhouri, et al.
Sleep Medicine|August 24, 2015
Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apneaNaim Alkhouri, Leila Kheirandish-Gozal, Ammar Matloob, et al.
BMJ Open|March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) studyNeeta B Amin, Amanda Darekar, Quentin M Anstee, et al.
Clinical and Translational Gastroenterology|November 11, 2016
A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its ComplicationsFlorian Rieder, Satya Kurada, David Grove, et al.
The Lancet. Gastroenterology & Hepatology|September 24, 2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a studyKenneth Cusi, Naim Alkhouri, Stephen A Harrison, et al.
Research Square|June 5, 2025
The Association between Neighborhood Context, Allostatic Load, and Metabolic Dysfunction-Associated Steatosis Liver Disease in Mexican-origin Farmworkers along the Southern Arizona US/Mexico BorderAdriana Maldonado, Emma Torres, Melissa Flores, et al.
Communications Medicine|January 3, 2023
A multistakeholder approach to innovations in NAFLD careJörn M Schattenberg, Alina M Allen, Helen Jarvis, et al.
Pageof 31

Showing results (231-240 of 306) with videos related to

Sort By:
Pageof 31
Alimentary Pharmacology & Therapeutics|December 13, 2022
A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitisZobair Younossi, Naim Alkhouri, Ken Cusi, et al.
Hepatology (Baltimore, Md.)|June 16, 2016
Receptor interacting protein 3 protects mice from high-fat diet-induced liver injurySanjoy Roychowdhury, Rebecca L McCullough, Carlos Sanz-Garcia, et al.
Journal of Hepatology|February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASHStephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Journal of Hepatology|December 15, 2010
An apoptosis panel for nonalcoholic steatohepatitis diagnosisTarek I Abu-Rajab Tamimi, Hesham M Elgouhari, Naim Alkhouri, et al.
Sleep Medicine|August 24, 2015
Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apneaNaim Alkhouri, Leila Kheirandish-Gozal, Ammar Matloob, et al.
BMJ Open|March 31, 2022
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) studyNeeta B Amin, Amanda Darekar, Quentin M Anstee, et al.
Clinical and Translational Gastroenterology|November 11, 2016
A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its ComplicationsFlorian Rieder, Satya Kurada, David Grove, et al.
The Lancet. Gastroenterology & Hepatology|September 24, 2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a studyKenneth Cusi, Naim Alkhouri, Stephen A Harrison, et al.
Research Square|June 5, 2025
The Association between Neighborhood Context, Allostatic Load, and Metabolic Dysfunction-Associated Steatosis Liver Disease in Mexican-origin Farmworkers along the Southern Arizona US/Mexico BorderAdriana Maldonado, Emma Torres, Melissa Flores, et al.
Communications Medicine|January 3, 2023
A multistakeholder approach to innovations in NAFLD careJörn M Schattenberg, Alina M Allen, Helen Jarvis, et al.
Pageof 31